Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02362997
Title Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope National Medical Center Duarte California 91010 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field